Abstract 196P
Background
Purpose: In the early analysis of START-NEW-ERA phase II trial, SAbR had optimal local control (LC) and promising OS without ≥G3 toxicity in unresectable LA-NSCLC patients unfit for concurrent chemo-radiotherapy. We report the 5-year outcomes with focus on patterns of local recurrence (LR).
Methods
and Materials: SAbR was delivered by V-MAT to primary tumor (T) and regional nodes (N) based on PET-CT. When thoracic failures occurred, we matched the SAbR planning with PET-CT images to accurately assess the LR location, precisely to determine in-field versus out-field recurrence, looking at the specific isodose line within which the LR occurred.
Results
50 unresectable LA-NSCLC patients unfit for concurrent ChTRT were enrolled. Median dose was 45 Gy and 40 Gy in 5 daily fractions to T and N, respectively. After a median follow-up of 72 months (range, 10–108) the 3-, 5-year PFS rates were 26 ± 6%, 26 ± 6%. The 3-, 5-year OS rates were 70 ± 6%, 46 ± 7%. No patients developed ≥G3 late toxicities. The 3-, 5-year LR-FS rates were 64 ± 7%, 64 ± 7%, respectively. Multivariate analysis revealed SCC (p 0.016) and SAbR dose
Conclusions
The 5-year outcomes of START-NEW-ERA trial confirm robust and sustained benefit in terms of safety and effectiveness of SAbR in LA-NSCLC patients unfit for concurrent chemo-radiotherapy. Clinical trial identification: NCT05291780.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.